BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies-Reference-Cited by-同舟云学术

BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies

Published:2014-01-23 Issue:8 Volume:28 Page:1657-1665
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Bogenberger J M,Kornblau S M,Pierceall W E,Lena R,Chow D,Shi C-X,Mantei J,Ahmann G,Gonzales I M,Choudhary A,Valdez R,Camoriano J,Fauble V,Tiedemann R E,Qiu Y H,Coombes K R,Cardone M,Braggio E,Yin H,Azorsa D O,Mesa R A,Stewart A K,Tibes R

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu201444.pdf

Reference47 articles.

1. Mesa RA, Tibes R . MPN blast phase: clinical challenge and assessing response. Leuk Res 2012; 36: 1496–1497.

2. Cherington C, Slack JL, Leis J, Adams RH, Reeder CB, Mikhael JR et al. Allogeneic stem cell transplantation for myeloproliferative neoplasm in blast phase. Leuk Res 2012; 36: 1147–1151.

3. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009; 10: 223–232.

4. Lubbert M, Suciu S, Baila L, Ruter BH, Platzbecker U, Giagounidis A et al. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. J Clin Oncol 2011; 29: 1987–1996.

5. Thepot S, Itzykson R, Seegers V, Raffoux E, Quesnel B, Chait Y et al. Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM). Blood 2010; 116: 3735–3742.

Cited by 169 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. TOPORS E3 ligase mediates resistance to hypomethylating agent cytotoxicity in acute myeloid leukemia cells;Nature Communications;2024-08-28

2. Long-term exposure and response to azacitidine for post-hematopoietic stem cell transplantation relapse of early T-cell precursor acute lymphoblastic leukemia: a case report and review of the literature;Leukemia & Lymphoma;2024-08-14

3. Newer combination treatments for breast cancer coexisting with acute myeloid leukemia in the novel regimens era: A case report and literature review;Oncology Letters;2024-07-23

4. Clinical Response to Azacitidine in Myelodysplastic Neoplasms is Associated with Distinct DNA Methylation Changes in Haematopoietic Stem and Progenitor cellsin vivo;2024-07-23

5. Chemotherapy-free treatment of VAF induces early and deep molecular response in patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: a prospective, single-center, single-arm, phase 2 trial;2024-07-12